Any current/future capex/capital investment/strategic investment?

Glenmark Life Sciences has recently commissioned additional capacities of 208 KL at Ankleshwar and 18 KL pharmaceutical capacity at Dahej (started operations in Q2 FY '25). Planned brownfield expansion includes adding an extra 60 KL pharma capacity at Ankleshwar in FY '26. Planning to add a total of 160 KL capacity at Dahej, expected to come online in FY '26. The Solapur facility is expected to add the first 200 KL of capacity by the end of Q3 FY '26 (though some references suggest FY '27). Capex guidance for FY '25 is between INR 300 crore to INR 350 crore, which includes land purchase for R&

Any current/future new fundraising through debt or equity?

Glenmark Life Sciences Limited is currently a debt-free company and has not reported any existing debt (Page 9). There is no mention of any ongoing or planned fundraising through debt in the call. Capital expenditure for FY '25 is expected to be between INR 300-350 crores, financed presumably from operational cash flows (Page 9). The company generated strong cash flows from operations of INR 134 crores in H1 FY '25 and has cash and equivalents of INR 446 crores, indicating sufficient liquidity (Page 5). No indications or announcements of any equity fundraising were made during the call. Overal

Future growth expectations in sales/revenue/volumes?

GLS expects high single-digit revenue growth for the full fiscal year FY '25, though earlier guidance was mid-teens, revised due to softness in Latin American markets (notably Argentina) and production disruptions. Robust order book and strong demand environment are anticipated to drive stronger momentum in H2 FY '25. Capacity expansions at Ankleshwar and Dahej will enhance volume deliveries in the current and coming years. Additional pharma capacity (60 KL at Ankleshwar and 160 KL at Dahej) planned for FY '26 to support growth. Medium-term growth is expected to improve, supported by new launc

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences expects high single-digit revenue growth for FY '25, revised down from earlier mid-teens guidance due to market softness in LatAm, especially Argentina. Strong growth is anticipated in H2 FY '25, supported by a robust order book and recovery of production lost in Q2. New CDMO projects are projected to add approximately $12 million in revenue at peak, expected to ramp up in H2 FY '26. Several product launches in North America, Russia, and other markets are expected to drive growth in the coming years. Base business demand remains steady except for Argentina, with potentia

Current/ Expected Orderbook/ Pending Orders?

Glenmark Life Sciences has a robust order book position heading into H2 FY '25, supporting expectations of strong growth. For the fourth CDMO project starting Q3 FY '25, purchase orders (POs) for Q3 and Q4 are already in place. The second new CDMO project expected to start in Q4 FY '25 might see a slight delay to the first half of next year due to regulatory approvals. The base CDMO business with 3 existing projects has orders intact but is lumpy, with some servicing issues impacting order fulfillment in Q2; these are expected to be made up in early Q3. Company is confident in fulfilling the e

Alivus Life Sciences LtdQ2 FY25Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,268.6P/E: 25.0Market Cap: ₹15.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

GLS expects high single-digit revenue growth for the full fiscal year FY '25, though earlier guidance was mid-teens, revised due to softness in Latin American markets (notably Argentina) and production disruptions.
Robust order book and strong demand environment are anticipated to drive stronger momentum in H2 FY '25.
Capacity expansions at Ankleshwar and Dahej will enhance volume deliveries in the current and coming years.
Additional pharma capacity (60 KL at Ankleshwar and 160 KL at Dahej) planned for FY '26 to support growth.
Medium-term growth is expected to improve, supported by new launches in North America, Russia, and other regions, plus expansion in CDMO business.
CDMO projects increasing from 3 to 5 next year will reduce lumpiness and contribute to faster growth.
Overall, the company targets early double-digit growth in generics and higher growth in CDMO post-FY '25.

Margin guidance

Category 3

Glenmark Life Sciences expects high single-digit revenue growth for FY '25, revised down from earlier mid-teens guidance due to market softness in LatAm, especially Argentina.
Strong growth is anticipated in H2 FY '25, supported by a robust order book and recovery of production lost in Q2.
New CDMO projects are projected to add approximately $12 million in revenue at peak, expected to ramp up in H2 FY '26.
Several product launches in North America, Russia, and other markets are expected to drive growth in the coming years.
Base business demand remains steady except for Argentina, with potential for medium-term higher growth due to new CDMO projects and regional launches.
Margins are expected to remain stable around 28% EBITDA, with gross margins maintained at 52-55%.
Capacity expansions and debottlenecking planned for FY '26 will support higher volumes and further growth.

See what Alivus Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Glenmark Life Sciences Limited is currently a debt-free company and has not reported any existing debt (Page 9).
There is no mention of any ongoing or planned fundraising through debt in the call.
Capital expenditure for FY '25 is expected to be between INR 300-350 crores, financed presumably from operational cash flows (Page 9).
The company generated strong cash flows from operations of INR 134 crores in H1 FY '25 and has cash and equivalents of INR 446 crores, indicating sufficient liquidity (Page 5).
No indications or announcements of any equity fundraising were made during the call.
Overall, the company appears to be funding growth and expansion through internal accruals without resorting to debt or equity raising at this time.

Order book

Yes

Glenmark Life Sciences has a robust order book position heading into H2 FY '25, supporting expectations of strong growth.
For the fourth CDMO project starting Q3 FY '25, purchase orders (POs) for Q3 and Q4 are already in place.
The second new CDMO project expected to start in Q4 FY '25 might see a slight delay to the first half of next year due to regulatory approvals.
The base CDMO business with 3 existing projects has orders intact but is lumpy, with some servicing issues impacting order fulfillment in Q2; these are expected to be made up in early Q3.
Company is confident in fulfilling the existing order book despite production challenges.
Overall visibility is positive, with capacity utilization near 95%, meaning order fulfillment is nearly at full throttle.

See what Alivus Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Glenmark Life Sciences has recently commissioned additional capacities of 208 KL at Ankleshwar and 18 KL pharmaceutical capacity at Dahej (started operations in Q2 FY '25).
Planned brownfield expansion includes adding an extra 60 KL pharma capacity at Ankleshwar in FY '26.
Planning to add a total of 160 KL capacity at Dahej, expected to come online in FY '26.
The Solapur facility is expected to add the first 200 KL of capacity by the end of Q3 FY '26 (though some references suggest FY '27).
Capex guidance for FY '25 is between INR 300 crore to INR 350 crore, which includes land purchase for R&D and other capacity expansions.
There is a mention of ongoing development of newer technology platforms (flow chemistry & other new platforms) with planned qualification and commercial runs in coming quarters/years.

Track Alivus Life Sciences Ltd — get its next earnings analysis in your feed

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlivus Life Sciences Ltd

Rev 4Mar 3

See where Alivus Life Sciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alivus Life Sciences Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →